Interestingly, we noticed that, except for one patient with a CBL mutation, no mutations related to RAS pathways (BRAF, KRAS, NRAS, and PTPN11) were identified in these MDS/MPN-RS-T patients (Figure 4E). This evidence concerns the gene KRAS and myeloproliferative neoplasm.